Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.

Abstract:

AIM:We developed a novel approach to efficiently deliver autologous tumor antigens to the cytoplasm of dendritic cells (DC) using yeast cell wall particles (YCWP). MATERIALS AND METHODS:Loading of YCWP, leakage of protein from loaded YCWP and cytoplasmic delivery of YCWP content was assessed using fluorescent-tagged experiments. Spectrophotometric analysis compared the epitope-specific T-cell responses following antigen presentation via YCWP versus exogenous loading. The in vivo effectiveness of tumor lysate (TL) particle loaded DC (TLPLDC) vaccine was assessed using murine melanoma models. RESULTS:In fluorescence-tagged experiments, YCWP efficiently delivered antigen to the cytoplasm of DC. TLPLDC loading was more effective than conventional exogenous loading of DC. Finally, in murine melanoma models, TLPLDC outperformed an analogous dendritoma vaccine. CONCLUSION:The TLPLDC vaccine is commercially scalable and holds the potential of producing personalized vaccines.

journal_name

Immunotherapy

journal_title

Immunotherapy

authors

Hardin MO,Vreeland TJ,Clifton GT,Hale DF,Herbert GS,Greene JM,Jackson DO,Berry JE,Nichols P,Yin S,Yu X,Wagner TE,Peoples GE

doi

10.2217/imt-2017-0114

subject

Has Abstract

pub_date

2018-04-01 00:00:00

pages

373-382

issue

5

eissn

1750-743X

issn

1750-7448

journal_volume

10

pub_type

杂志文章
  • The split personality of NKT cells in malignancy, autoimmune and allergic disorders.

    abstract::NKT cells are a heterogeneous subset of specialized, self-reactive T cells, with innate and adaptive immune properties, which allow them to bridge innate and adaptive immunity and profoundly influence autoimmune and malignant disease outcomes. NKT cells mediate these activities through their ability to rapidly express...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.117

    authors: Subleski JJ,Jiang Q,Weiss JM,Wiltrout RH

    更新日期:2011-10-01 00:00:00

  • First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.

    abstract::Aim: To evaluate treatment results in advanced/metastatic melanoma patients treated with anti-PD-1 immunotherapy in routine practice in oncology centers in Poland. Methods: Multicenter retrospective analysis included 499 patients with unresectable/metastatic (stage IIIC-IV) melanoma treated with anti-PD-1 in first-lin...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0217

    authors: Cybulska-Stopa B,Pacholczak-Madej R,Kamińska-Winciorek G,Ziętek M,Czarnecka AM,Piejko K,Galus Ł,Ziółkowska B,Kieszko S,Kempa-Kamińska N,Calik J,Rolski J,Sałek-Zań A,Gajewska-Wicher K,Drosik-Kwaśniewska A,Rogala P,Kubiatow

    更新日期:2021-03-01 00:00:00

  • Conference scene: progress with promising human antibodies.

    abstract::Antibodies and antibody-based therapeutics have become big business, with annual sales over US$50 billion, accounting for >6% of worldwide pharmaceutical revenues. Ten molecules have blockbuster status (>US$1 billion), with six generating more than US$6 billion in sales. In excess of 300 products based on this rapidly...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.5

    authors: Larrick JW

    更新日期:2012-03-01 00:00:00

  • Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.

    abstract::Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/O...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0266

    authors: Moreau P,Hebraud B,Facon T,Leleu X,Hulin C,Hashim M,Hu Y,Caillot D,Benboubker L,Zweegman S,Merz M,Weisel K,Salwender H,Mai EK,Goldschmidt H,Bertsch U,Vanquickelberghe V,Kampfenkel T,Boer C,Krotneva S,Proskorovsky

    更新日期:2021-02-01 00:00:00

  • Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from 'Immunotherapy Bridge'.

    abstract::Over the last few years, extensive research has improved our understanding of tumor immunology and has enabled the development of novel treatments. The state of the art of immunotherapy in various types of malignancies was exhaustively discussed in the 'Immunotherapy Bridge' meeting, which was held in Naples on 4-5 De...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0042

    authors: Ascierto PA,Garbe C

    更新日期:2020-02-01 00:00:00

  • The role of the microbiome in childhood asthma.

    abstract::It is now well established that the healthy bronchial tree contains a microbiome distinct from that of the upper respiratory tract and that the lung microbiome may be dysregulated in individuals with a chronic respiratory disease, such as asthma. In addition, after birth, gut microbes interact with the host tissue, es...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0048

    authors: Pisi G,Fainardi V,Aiello M,Bertorelli G,Crisafulli E,Chetta A

    更新日期:2017-11-01 00:00:00

  • NK cells and their receptors during viral infections.

    abstract::Increasing evidence indicates the importance of human natural killer (NK) cells in the immune response against certain viral infections. In the present article, we summarize information on NK cell responses against several viruses and on the nature of NK cell receptor-ligand interactions involved in these responses. R...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.99

    authors: Marcenaro E,Carlomagno S,Pesce S,Della Chiesa M,Parolini S,Moretta A,Sivori S

    更新日期:2011-09-01 00:00:00

  • Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.

    abstract::The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effec...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.90

    authors: Al Yaghchi C,Zhang Z,Alusi G,Lemoine NR,Wang Y

    更新日期:2015-01-01 00:00:00

  • Antibody-based immunotherapy of solid cancers: progress and possibilities.

    abstract::Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host-tumor interaction has defined a new range of targets fo...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.57

    authors: Nicodemus CF

    更新日期:2015-01-01 00:00:00

  • Immunotherapy for TB.

    abstract::Mycobacterium tuberculosis was one of the first human pathogens to be identified as the cause of a specific disease--TB. TB was also one of the first specific diseases for which immunotherapy was attempted. In more than a century since, multiple different immunotherapies have been attempted, alongside vaccination and ...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.12.52

    authors: Doherty TM

    更新日期:2012-06-01 00:00:00

  • Checkpoint inhibition in meningiomas.

    abstract::Meningiomas are increasingly appreciated to share similar features with other intra-axial central nervous system neoplasms as well as systemic cancers. Immune checkpoint inhibition has emerged as a promising therapy in a number of cancers, with durable responses of years in a subset of patients. Several lines of evide...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2016-0017

    authors: Bi WL,Wu WW,Santagata S,Reardon DA,Dunn IF

    更新日期:2016-06-01 00:00:00

  • Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?

    abstract::Evaluation of: Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 171, 237-242 (2012). Clinical trials of a humanized anti-IL-6 receptor antibody, tocilizumab (TCZ), proved...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.47

    authors: Tanaka T

    更新日期:2013-07-01 00:00:00

  • JAK2 inhibition in murine systemic lupus erythematosus.

    abstract::Systemic lupus erythematosus is a systemic autoimmune disease characterized by the presence of myriad autoantibodies, some with pathogenic potential, and diverse clinical manifestations. Involvement of the kidney is a major cause of morbidity and mortality in human lupus patients and in murine models of the disease. I...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.20

    authors: Tagoe C,Putterman C

    更新日期:2012-04-01 00:00:00

  • Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

    abstract::HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 respo...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2016-0052

    authors: De La Cruz LM,Nocera NF,Czerniecki BJ

    更新日期:2016-10-01 00:00:00

  • Jacalin regulates IgA production by peripheral blood mononuclear cells.

    abstract:AIMS:In IgA nephropathy, circulating immune complexes containing IgA1 are deposited on the glomerular mesangium, causing mesangial cell proliferation and acceleration of extracellular matrix production. The suppressive effect of jacalin, a galactose-binding lectin, on IgA production in vitro was determined. MATERIALS ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.125

    authors: Miyamoto K,Chiba T,Shinohara N,Nagata Y,Asakawa N,Kato S,Mizutani N,Murata T,Nomura S,Horiuchi T

    更新日期:2012-12-01 00:00:00

  • Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.

    abstract::Since the discovery of the CD40-CD154 costimulatory pathway and its critical role in the adaptive immune response, there has been considerable interest in therapeutically targeting this interaction with monoclonal antibodies in transplantation. Unfortunately, initial promise in animal models gave way to disappointment...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.1

    authors: Pinelli DF,Ford ML

    更新日期:2015-01-01 00:00:00

  • Preventing stem cell transplantation-associated viral infections using T-cell therapy.

    abstract::Hematopoietic stem cell transplantation is the treatment of choice for many hematologic malignancies and genetic diseases. However, viral infections continue to account for substantial post-transplant morbidity and mortality. While antiviral drugs are available against some viruses, they are associated with significan...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.43

    authors: Tzannou I,Leen AM

    更新日期:2015-01-01 00:00:00

  • The safety profile of Polyoxidonium in daily practice: results from postauthorization safety study in Slovakia.

    abstract:AIM:This study assessed the safety of Polyoxidonium® 6 mg lyophilisate for solution for injection in routine practice with a special focus on signs or symptoms of potential adverse renal effects. MATERIALS & METHODS:A local, multicenter, prospective, open-label, noninterventional, uncontrolled postauthorization safety...

    journal_title:Immunotherapy

    pub_type: 杂志文章,多中心研究

    doi:10.2217/imt-2017-0116

    authors: Pružinec P,Chirun N,Sveikata A

    更新日期:2018-02-01 00:00:00

  • Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory.

    abstract::Brain tumors present unique therapeutic challenges and they include glioblastoma (GBM) and metastases from cancers of other organs. Current treatment options are limited and include surgical resection, radiation therapy, laser interstitial thermal therapy and chemotherapy. Although much research has been done on the d...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2019-0023

    authors: Liu Y,Chongsathidkiet P,Crawford BM,Odion R,Dechant CA,Kemeny HR,Cui X,Maccarini PF,Lascola CD,Fecci PE,Vo-Dinh T

    更新日期:2019-10-01 00:00:00

  • Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer.

    abstract::Despite novel chemotherapy treatments, pancreatic ductal adenocarcinoma (PDA) remains a lethal disease. New targeted cancer vaccines may represent a viable option for patients with PDA. The Wilms' tumor 1 (WT1) antigen is one of the most widely expressed tumor-associated antigens in various types of tumors, including ...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2016-0031

    authors: Koido S,Okamoto M,Shimodaira S,Sugiyama H

    更新日期:2016-11-01 00:00:00

  • Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice.

    abstract:AIM:There is still no specific therapy for infection with the highly pathogenic avian influenza A virus (HPAI) H5N1, which caused 39 human cases with a 64% fatality rate in 2013. MATERIALS & METHODS:We prepared highly purified specific equine polyclonal immunoglobulin fragments (F(ab')2) against H5N1 and tested them f...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.14.40

    authors: Herbreteau CH,Jacquot F,Rith S,Vacher L,Nguyen L,Carbonnelle C,Lotteau V,Jolivet M,Raoul H,Buchy P,Saluzzo JF

    更新日期:2014-01-01 00:00:00

  • Genetic modification of natural killer cells for adoptive cellular immunotherapy.

    abstract::Immunotherapy of cancer is a rapidly developing field; one such development is the manipulation and use of natural killer (NK) cells. These cells with 'killer instincts' are an attractive cell to utilize, as they are directly reactive toward tumor and could potentially activate the endogenous adaptive immune system. T...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.09.36

    authors: Pegram HJ,Kershaw MH,Darcy PK

    更新日期:2009-07-01 00:00:00

  • Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis.

    abstract::Chronic rhinosinusitis with nasal polyposis (CRSwNP) imparts a significant healthcare challenge, resulting in diminished quality of life for patients and high costs with resource utilization for disease management. Understanding of CRSwNP pathophysiology has progressively evolved and the identification of various infl...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2019-0191

    authors: Boyle JV,Lam K,Han JK

    更新日期:2020-02-01 00:00:00

  • Mechanisms of immunomodulation in human glioblastoma.

    abstract::Glioblastoma multiforme (GBM), WHO grade IV astrocytoma, is the most dramatic primary brain cancer with a very poor prognosis due to inevitable disease recurrence. Less than 10% of GBM patients are still alive 5 years after diagnosis despite a multimodal treatment with surgical resection of the tumor, radiation therap...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.39

    authors: Avril T,Vauleon E,Tanguy-Royer S,Mosser J,Quillien V

    更新日期:2011-04-01 00:00:00

  • Interview: Investigating immunomodulators among the Actinomycetales. Interview by Hannah Wilson.

    abstract::John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical Schoo...

    journal_title:Immunotherapy

    pub_type: 面试,新闻

    doi:10.2217/imt.13.27

    authors: Stanford JL

    更新日期:2013-05-01 00:00:00

  • Timely blockade of ICAM-1.LFA-1 interaction prevents disease onset in a mouse model of emphysema.

    abstract:AIM:It is becoming apparent that emphysema is partly driven by self-reactive T cells inducing inflammatory damage. Thus, T cells become targets for therapy similar to other autoimmune diseases. Costimulatory blockade therapy targets disease-specific T cells, rendering them ineffective by blocking a necessary costimulat...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.15.31

    authors: Newton AH,Danahy DB,Chan MA,Benedict SH

    更新日期:2015-01-01 00:00:00

  • CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.

    abstract::Following cancer treatment, patients often report behavioral and cognitive changes. Novel cancer immunotherapeutics have the potential to produce sustained cancer survivorship, meaning patients will live longer with the side effects of treatment. Given the role of inflammatory pathways in mediating behavioral and cogn...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0056

    authors: McGinnis GJ,Raber J

    更新日期:2017-09-01 00:00:00

  • Heat-shock proteins in diagnosis and treatment: an overview of different biochemical and immunological functions.

    abstract::Heat-shock proteins (HSPs) have been involved in different functions including chaperone activity, protein folding, apoptosis, autophagy and immunity. The HSP families have powerful effects on the stimulation of innate immune responses through Toll-like receptors and scavenger receptors. Moreover, HSP-mediated phagocy...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2018-0105

    authors: Milani A,Basirnejad M,Bolhassani A

    更新日期:2019-02-01 00:00:00

  • Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer.

    abstract::Background: Progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies. In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 tria...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0202

    authors: Philipovskiy A,Chambers K,Konstantinidis I,McCallum R,Corral J,Gaur S

    更新日期:2020-12-01 00:00:00

  • A novel microcrystalline tyrosine-adsorbed, mite-allergoid subcutaneous immunotherapy: 1-year follow-up report.

    abstract:AIM:A 1-year follow-up study comparing the safety and tolerability of the dosing schedules, satisfaction and effectiveness of a novel microcrystalline tyrosine-adsorbed mite (Dermatophagoides pteronyssinus)-allergoid subcutaneous immunotherapy (Acarovac Plus™) in 30 adult patients (18-65 years) with allergic rhinitis a...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2016-0068

    authors: Roger A,Depreux N,Jurgens Y,Serra AT,Heath MD,Garcia G,Skinner MA

    更新日期:2016-10-01 00:00:00